Therapeutic developments in pancreatic cancer
ZI Hu, EM O'Reilly - Nature Reviews Gastroenterology & Hepatology, 2024 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …
lethal human malignancies. Much is known regarding the biology and pathophysiology of …
DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities
Y Abuetabh, HH Wu, C Chai, H Al Yousef… - … & molecular medicine, 2022 - nature.com
Antitumor therapeutic strategies that fundamentally rely on the induction of DNA damage to
eradicate and inhibit the growth of cancer cells are integral approaches to cancer therapy …
eradicate and inhibit the growth of cancer cells are integral approaches to cancer therapy …
Targeted therapy and mechanisms of drug resistance in breast cancer
Simple Summary Internationally, in women, breast cancer (BC) is the most common cancer
type and is the leading cause of cancer-related death. There are two main histological …
type and is the leading cause of cancer-related death. There are two main histological …
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
C Stossel, M Raitses-Gurevich, D Atias, T Beller… - Cancer discovery, 2023 - AACR
Germline BRCA–associated pancreatic ductal adenocarcinoma (gl BRCA PDAC) tumors are
susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with gl …
susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with gl …
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer
N Gupta, TT Huang, S Horibata, JM Lee - Pharmacological research, 2022 - Elsevier
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …
PARP1 proximity proteomics reveals interaction partners at stressed replication forks
PARP1 mediates poly-ADP-ribosylation of proteins on chromatin in response to different
types of DNA lesions. PARP inhibitors are used for the treatment of BRCA1/2-deficient …
types of DNA lesions. PARP inhibitors are used for the treatment of BRCA1/2-deficient …
Homologous recombination proficiency in ovarian and breast cancer patients
JF Creeden, NS Nanavaty, KR Einloth, CE Gillman… - BMC cancer, 2021 - Springer
Homologous recombination and DNA repair are important for genome maintenance.
Genetic variations in essential homologous recombination genes, including BRCA1 and …
Genetic variations in essential homologous recombination genes, including BRCA1 and …
Mechanisms of drug resistance in ovarian cancer and associated gene targets
KL Alatise, S Gardner, A Alexander-Bryant - Cancers, 2022 - mdpi.com
Simple Summary When tumors become resistant to chemotherapeutics, alternative
treatment strategies must be explored. Gene targeting provides a personalized and …
treatment strategies must be explored. Gene targeting provides a personalized and …
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
PS Patel, A Algouneh, R Hakem - Oncogene, 2021 - nature.com
The principle of synthetic lethality, which refers to the loss of viability resulting from the
disruption of two genes, which, individually, do not cause lethality, has become an attractive …
disruption of two genes, which, individually, do not cause lethality, has become an attractive …
Development of synthetic lethality in cancer: molecular and cellular classification
S Li, W Topatana, S Juengpanich, J Cao, J Hu… - … and Targeted Therapy, 2020 - nature.com
Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic
lethality provides a new approach for the treatment of mutated genes that were previously …
lethality provides a new approach for the treatment of mutated genes that were previously …